Active, not recruitingPhase 3NCT06208215
RZ358 Treatment for Congenital Hyperinsulinism
Studying Hyperinsulinemic hypoglycaemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rezolute
- Principal Investigator
- Gopal Saha, MDRezolute
- Intervention
- RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 45 years · All sexes
- Timeline
- 2024 – 2027
Study locations (18)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- Rezolute Investigative Site, Varna, Bulgaria, Varna, Bulgaria
- Rezolute Investigative Site, Odense, Denmark, Odense, Denmark
- Rezolute Investigative Site, Bron, France, Bron, France
- Rezolute Investigative Site, Paris, France, Paris, France
- Rezolute Investigative Site, Tbilisi, Georgia, Tbilisi, Georgia
- Rezolute Investigative Site, Berlin, Germany, Berlin, Germany
- Rezolute Investigative Site, Dusseldorf, Germany, Düsseldorf, Germany
- Rezolute Investigative Site, Athens, Greece, Athens, Greece
- Rezolute Investigative Site, Seeb, Oman, Seeb, Oman
- Rezolute Investigative Site, Al Rayyan, Qatar, Al Rayyan, Qatar
- Rezolute Investigative Site, Barcelona, Spain, Barcelona, Spain
- Rezolute Investigative Site, Sevilla, Spain, Seville, Spain
- Rezolute Investigative Site, Ankara, Turkey, Ankara, Turkey (Türkiye)
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06208215 on ClinicalTrials.govOther trials for Hyperinsulinemic hypoglycaemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04732416HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Hanmi Pharmaceutical Company Limited
- ACTIVE NOT RECRUITINGPHASE3NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismZealand Pharma
- RECRUITINGPHASE2NCT0420560418FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismMiguel Pampaloni
- RECRUITINGPHASE1NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and InsulinomaCook Children's Health Care System